Frank Fenner to retire at (almost) 93.

Stem Cell Sciences adds pericyte cell types to list of products for research.

At AusBiotech's targeting tumours session next week, Minomic's CEO, Brad Walsh, will explain how proteomics can be harnessed to diagnose disease.

ReWire Therapies can probably boast one of the most impressive groups of company directors to be found in any biotechnology venture in Australia.

Adelaide company Oncaidia is developing a novel monoclonal antibody it hopes will target cancer by tracking down the La protein and letting loose a firestorm.

In this interview, futurologist Ian Pearson talks about his profession, explains why he doesn't think we will understand intelligent machines when they finally arise, and discusses the convergence of nanoscience, biotechnology, information technology and cognitive science.

As it begins Phase IIa clinical trials, Mesoblast is riding high: its share price is climbing, its market capitalisation is booming and all that promise seems to be coming good.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

New head for Melbourne's Genetic Technologies as founder steps back.

No one is completely certain of the exact role of paraspeckles, but most suspect they are involved in gene expression.

Fish is brain food and for most of us that means eating it. For Michael Lardelli, zebrafish are also helping us understand the human brain.